Evidence map›Paper›PMID 41892959›Full record

ArticleMarine drugs2026

Polydeoxyribonucleotide (PDRN) Selectively Promotes Osteoblast Differentiation Without Affecting Osteoclastogenesis.

Younghoon Jeon, Eunjung Heo, Xian Jin, Dong-Kyo Lee, Xiangguo Che, Hyun-Ju Kim, Sung-Hye Byun, Je-Yong Choi, Jeongkyu Choi, Jinyoung Oh

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Marine drugs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Younghoon JeonDepartment of Anesthesiology and Pain Medicine, School of Medicine Kyungpook National University, Daegu 41944, Republic of Korea.
Eunjung HeoDepartment of Biochemistry and Cell Biology, Cell and Matrix Research Institute, School of Medicine, Kyungpook National University, Daegu 41944, Republic of Korea.ORCID 0009-0007-8851-3730
Xian JinDepartment of Biochemistry and Cell Biology, Cell and Matrix Research Institute, School of Medicine, Kyungpook National University, Daegu 41944, Republic of Korea.
Dong-Kyo LeeDepartment of Biochemistry and Cell Biology, Cell and Matrix Research Institute, School of Medicine, Kyungpook National University, Daegu 41944, Republic of Korea.
Xiangguo CheDepartment of Biochemistry and Cell Biology, Cell and Matrix Research Institute, School of Medicine, Kyungpook National University, Daegu 41944, Republic of Korea.
Hyun-Ju KimDepartment of Biochemistry and Cell Biology, Cell and Matrix Research Institute, School of Medicine, Kyungpook National University, Daegu 41944, Republic of Korea.ORCID 0000-0002-5836-5841
Sung-Hye ByunDepartment of Anesthesiology and Pain Medicine, School of Medicine Kyungpook National University, Daegu 41944, Republic of Korea.ORCID 0000-0002-9287-5087
Je-Yong ChoiDepartment of Biochemistry and Cell Biology, Cell and Matrix Research Institute, School of Medicine, Kyungpook National University, Daegu 41944, Republic of Korea.ORCID 0000-0002-5057-8842
Jeongkyu ChoiDepartment of Anesthesiology and Pain Medicine, Kyungpook National University Hospital, Daegu 41944, Republic of Korea.
Jinyoung OhDepartment of Anesthesiology and Pain Medicine, School of Medicine Kyungpook National University, Daegu 41944, Republic of Korea.ORCID 0000-0003-3562-908X

Funding

Biomedical Research Institute grant from Kyungpook National University Hospital 2023
6 · The paper itself

Abstract

Developing novel anabolic agents for bone regeneration remains a clinical priority. Polydeoxyribonucleotide (PDRN) exhibits tissue-regenerative properties, but its direct cellular effects on bone remodeling remain unclear. This in vitro study investigated PDRN's effects on osteoblast (MC3T3-E1) and osteoclast (primary bone marrow-derived macrophages) differentiation. We evaluated metabolic activity, gene/protein expression, and specific differentiation markers using MTS, qRT-PCR, Western blotting, and functional assays (ALP, Alizarin Red S, TRAP, pit formation). In osteoblasts, PDRN dose-dependently modulated metabolic activity while upregulating the early transcription factor Runx2. PDRN significantly enhanced osteoblast differentiation, evidenced by increased ALP activity, elevated mineralized matrix deposition, and robust upregulation of osteocalcin and Runx2. Conversely, PDRN exhibited no direct effect on osteoclast precursor metabolic activity, differentiation, or resorptive function. These findings support a working hypothesis in which PDRN selectively promotes osteoblast differentiation without directly affecting osteoclastogenesis. While further pharmacological investigations are required to definitively elucidate the specific purinergic receptor mechanisms, our results highlight PDRN as a promising candidate anabolic agent for bone regeneration.

Indexed as

Cell DifferentiationOsteoblastsOsteoclastsOsteogenesisPolydeoxyribonucleotidesAnimalsBone RegenerationCell LineCore Binding Factor Alpha 1 SubunitMiceOsteocalcinCore Binding Factor Alpha 1 SubunitOsteocalcinPolydeoxyribonucleotidesadenosine A2A receptorbone regenerationdifferentiationosteoblastosteoclastpolydeoxyribonucleotide

Identifiers

PMID41892959
PMCPMC13028593

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.